Heterocyclic compounds and uses thereof

• US 8,785,470 B2
• Filed: 07/18/2012
• Issued: 07/22/2014
• Est. Priority Date: 08/29/2011
• Status: Active Grant

• Current Assignee: Infinity Pharmaceuticals, Inc.
• Original Assignee: Infinity Pharmaceuticals, Inc.
• Inventors: Castro, Alfredo C., Evans, Catherine A., Janardanannair, Somarajannair, Lescarbeau, Andre, Liu, Tao, Snyder, Daniel A., Tremblay, Martin R., Ren, Pingda, Liu, Yi, Li, Liansheng, Chan, Katrina
• Primary Examiner(s): Ward, Paul V.
• Application Number:
  US13/552,516
• Publication Number:
  US 20130053362A1
• Time in Patent Office: 734 Days
• Field of Search: 544/283, 544/266.2, 514/266.1, 514/283
• US Class Current: 514/283
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 411/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 495/04 Ortho-condensed systems
• CPC Class Codes: C07D 513/04 : Ortho-condensed systems
• CPC Class Codes: C12N 9/1205 : Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
• CPC Class Codes: C12Y 207/01137 : Phosphatidylinositol 3-kinase (2.7.1.137)
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Claims

1. A compound of the formula:

2. The compound of claim 1, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt or enantiomer.

7. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 55%.

8. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 75%.

9. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 90%.

10. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 95%.

11. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 98%.

12. The compound of claim 2, wherein the compound has an (S)-enantiomeric excess of greater than 99%.

13. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

14. A pharmaceutical composition comprising a compound according to claim 2 and one or more pharmaceutically acceptable excipients.

19. A pharmaceutical composition comprising a compound according to claim 7 and one or more pharmaceutically acceptable excipients.

20. A pharmaceutical composition comprising a compound according to claim 8 and one or more pharmaceutically acceptable excipients.

21. A pharmaceutical composition comprising a compound according to claim 9 and one or more pharmaceutically acceptable excipients.

22. A pharmaceutical composition comprising a compound according to claim 10 and one or more pharmaceutically acceptable excipients.

23. A pharmaceutical composition comprising a compound according to claim 11 and one or more pharmaceutically acceptable excipients.

24. A pharmaceutical composition comprising a compound according to claim 12 and one or more pharmaceutically acceptable excipients.

3. A compound of the formula:

15. A pharmaceutical composition comprising a compound according to claim 3 and one or more pharmaceutically acceptable excipients.

4. A compound of the formula:

5. The compound of claim 4, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt or enantiomer.

16. A pharmaceutical composition comprising a compound according to claim 4 and one or more pharmaceutically acceptable excipients.

17. A pharmaceutical composition comprising a compound according to claim 5 and one or more pharmaceutically acceptable excipients.

6. A compound of the formula:

18. A pharmaceutical composition comprising a compound according to claim 6 and one or more pharmaceutically acceptable excipients.